- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06335173
Uno studio per valutare l'efficacia e la sicurezza dell'ACU193 per via endovenosa nei partecipanti con malattia di Alzheimer in fase iniziale (ALTITUDE-AD) (ALTITUDE-AD)
Uno studio di progettazione adattiva di fase 2/3, in doppio cieco, randomizzato, controllato con placebo per valutare l'efficacia e la sicurezza dell'ACU193 per via endovenosa nella malattia di Alzheimer in fase iniziale
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
British Columbia
-
Kelowna, British Columbia, Canada
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa, Ontario, Canada
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto, Ontario, Canada
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park, Quebec, Canada
- MoCA Research and Innovations
-
-
-
-
-
Berlin, Germania
- Charité - Universitaetsmedizin Berlin
-
Cologne, Germania
- University Hospital of Cologne
-
Mannheim, Germania
- Zentralinstitut für seelische Gesundheit
-
Munich, Germania
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
-
-
-
Bristol, Regno Unito
- Re:Cognition Health - Bristol
-
-
Greater London
-
London, Greater London, Regno Unito
- Re:Cognition Health - London
-
London, Greater London, Regno Unito
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester, Hampshire, Regno Unito
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell, Lanarkshire, Regno Unito
- Neuroclin Glasgow
-
-
Lancashire
-
Preston, Lancashire, Regno Unito
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford, Surrey, Regno Unito
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield, Yorkshire, Regno Unito
- Panthera Biopartners - Sheffield
-
-
-
-
-
Barcelona, Spagna
- Fundacio ACE
-
Donostia / San Sebastian, Spagna
- Policlínica Gipuzkoa
-
Getxo, Spagna
- Cae Oroitu
-
Madrid, Spagna
- Hospital Ruber
-
Seville, Spagna
- Hospital Victoria Eugenia
-
Valencia, Spagna
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès, Barcelona, Spagna
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva, Zaragoza, Spagna
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
California
-
Carlsbad, California, Stati Uniti, 92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton, California, Stati Uniti, 92835
- Neurology Center of North Orange County
-
Irvine, California, Stati Uniti, 92614
- Irvine Medical Research
-
Long Beach, California, Stati Uniti, 90804
- Healthy Brain Research
-
Santa Ana, California, Stati Uniti, 92705
- Syrentis Clinical Research
-
Sherman Oaks, California, Stati Uniti, 91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk, Connecticut, Stati Uniti, 06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis, Florida, Stati Uniti, 33462
- JEM Research Institute
-
Bradenton, Florida, Stati Uniti, 34205
- Bradenton Research Center
-
Coral Gables, Florida, Stati Uniti, 33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach, Florida, Stati Uniti, 33445
- Brain Matters Research
-
Homestead, Florida, Stati Uniti, 33032
- Coral Clinical Research
-
Lady Lake, Florida, Stati Uniti, 32159
- K2 Medical Research - Villages
-
Miami, Florida, Stati Uniti, 33126
- Finlay Medical Research
-
Naples, Florida, Stati Uniti, 34105-8522
- Aqualane Clinical Research
-
Ocala, Florida, Stati Uniti, 34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange, Florida, Stati Uniti, 32127
- Progressive Medical Research
-
Stuart, Florida, Stati Uniti, 34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa, Florida, Stati Uniti, 33607
- K2 Medical Research - Tampa
-
The Villages, Florida, Stati Uniti, 32162
- Charter Research - Lady Lake
-
Wellington, Florida, Stati Uniti, 33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park, Florida, Stati Uniti, 32789
- Conquest Research
-
Winter Park, Florida, Stati Uniti, 32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus, Georgia, Stati Uniti, 31909
- Columbus Memory Center
-
Decatur, Georgia, Stati Uniti, 30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook, Illinois, Stati Uniti, 60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton, Massachusetts, Stati Uniti, 02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg, Mississippi, Stati Uniti, 39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth, New Hampshire, Stati Uniti, 03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield, New Jersey, Stati Uniti, 07081
- The Cognitive and Research Center of New Jersey
-
Toms River, New Jersey, Stati Uniti, 08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews, North Carolina, Stati Uniti, 28105
- AMC Research
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97210
- Summit Research Network
-
-
Pennsylvania
-
Abington, Pennsylvania, Stati Uniti, 19001
- Abington Neurological Associates
-
Norristown, Pennsylvania, Stati Uniti, 19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Stati Uniti, 02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova, Tennessee, Stati Uniti, 38018
- Neurology Clinic. P.C
-
Knoxville, Tennessee, Stati Uniti, 37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin, Texas, Stati Uniti, 78757
- Senior Adult Specialty Research
-
Beaumont, Texas, Stati Uniti, 77702
- Gadolin Research, LLC
-
Dallas, Texas, Stati Uniti, 75231
- Kerwin Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
Sperimentale: DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
Comparatore placebo: DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
Sperimentale: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Lasso di tempo: Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di partecipanti con eventi avversi correlati al trattamento (TEAE)
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Numero di partecipanti con eventi avversi gravi (SAE) ed eventi avversi di particolare interesse (AESI)
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Numero di partecipanti che interrompono o si ritirano a causa del TEAE
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Numero di partecipanti con anticorpi antifarmaco (ADA) e anticorpi neutralizzanti
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Numero di partecipanti con anomalie dell'imaging correlate all'amiloide con edema/versamenti (ARIA-E) e ARIA con emorragia/deposizione di emosiderina (ARIA-H) misurati mediante risonanza magnetica (MRI)
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Concentrazioni nel liquido cerebrospinale di ACU193 in un sottoinsieme di partecipanti
Lasso di tempo: Fino alla settimana 76
|
Fino alla settimana 76
|
|
|
Variazione rispetto al basale del carico o della deposizione della placca amiloide misurata mediante tomografia a emissione di positroni (PET) nei centriloidi
Lasso di tempo: Riferimento fino alla settimana 76
|
Riferimento fino alla settimana 76
|
|
|
Variazione rispetto al basale nella risonanza magnetica volumetrica (vMRI) del volume dell'intero cervello, del volume ventricolare e del volume di regioni di interesse selezionate
Lasso di tempo: Riferimento fino alla settimana 76
|
Riferimento fino alla settimana 76
|
|
|
Variazione rispetto al basale delle concentrazioni di amiloide, tau e altri biomarcatori neurodegenerativi nel liquido cerebrospinale
Lasso di tempo: Riferimento fino alla settimana 76
|
Riferimento fino alla settimana 76
|
|
|
Variazione rispetto al basale delle concentrazioni di amiloide, tau e altri biomarcatori neurodegenerativi nel liquido cerebrospinale in un sottogruppo di partecipanti
Lasso di tempo: Riferimento fino alla settimana 76
|
Riferimento fino alla settimana 76
|
|
|
Variazione rispetto al basale delle concentrazioni ematiche di amiloide, tau e altri biomarcatori neurodegenerativi
Lasso di tempo: Riferimento fino alla settimana 76
|
Riferimento fino alla settimana 76
|
|
|
Effetto di sabirnetug sulla progressione clinica rispetto al placebo valutato utilizzando l'analisi del tempo risparmiato misurato da iADRS
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Effetto di sabirnetug sulla progressione clinica rispetto al placebo valutato utilizzando l'analisi del risparmio di tempo misurato da ADCS-iADL
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Effetto di sabirnetug sulla progressione clinica rispetto al placebo valutato utilizzando l'analisi del tempo risparmiato misurato da ADAS-Cog13
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Effetto di sabirnetug sulla progressione clinica rispetto al placebo valutato utilizzando l'analisi del risparmio di tempo misurato da CDR-SB
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Effetto di sabirnetug sulla progressione clinica rispetto al placebo valutato utilizzando l'analisi del risparmio di tempo misurato dal MMSE
Lasso di tempo: Riferimento fino alla settimana 80
|
Riferimento fino alla settimana 80
|
|
|
Concentrazione sierica di sabirnetug
Lasso di tempo: Pre-dose e più punti temporali post-dose fino a 80 settimane
|
Pre-dose e più punti temporali post-dose fino a 80 settimane
|
|
|
Concentrazione di sabirnetug nel liquido cerebrospinale (CSF)
Lasso di tempo: Fino alla settimana 76
|
Fino alla settimana 76
|
|
|
Coinvolgimento del target valutato mediante misurazione del complesso sabirnetug-oligomero amiloide-β (AβO) nel liquido cerebrospinale
Lasso di tempo: Fino alla settimana 76
|
Fino alla settimana 76
|
|
|
Change from Baseline in ADCS-iADL Score
Lasso di tempo: Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
Lasso di tempo: Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Lasso di tempo: Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
Lasso di tempo: Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
Lasso di tempo: Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
Lasso di tempo: Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
Lasso di tempo: Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
Lasso di tempo: Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
Lasso di tempo: Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
Lasso di tempo: Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Lasso di tempo: Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
Lasso di tempo: Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
Lasso di tempo: Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disordini mentali
- Manifestazioni neurocomportamentali
- Disturbi neurocognitivi
- Disturbi cognitivi
- Demenza
- Tauopatie
- Malattie Neurodegenerative
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Disfunzione cognitiva
- Malattia di Alzheimer
- Disturbi della memoria
Altri numeri di identificazione dello studio
- ACU193-201
- 2023-509807-34-00 (Identificatore di registro: EU CT Number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .